| | APRIL - 202119UTLOOKHealthcare Tech When using enhanced endoscopic imaging, lesions can be differentiated but it take more time and training and experience in order to use it effectively. Still, the specificity and sensitivity of obtaining a positive biopsy are low. With SPECTRA IMDxTM, when a clinician is suspecting a lesion, he uses the IMDx Raman probe to contact the suspicious lesion to obtain real-time feedback if the tissue in question is of a high risk of early gastric cancer. At the same time, clinicians can obtain better yield in their biopsies and also gets the opportunity to decide in-situ what course of actions can be undertaken. As the solution leverages Raman Spectroscopy to identify the molecular makeup of the tissue, it interrogates with low-powered near-infrared laser. The resulting Raman spectrum emitted from the molecular bonds within the tissue is like a fingerprint that is specific to its molecular makeup. Utilizing an AI machine learning algorithm trained with thousands of data sets, SPECTRA IMDxTM can identify the measured Raman spectrum that is of a high risk of being early gastric cancer.The uniqueness of Endofotonics stems from its SPECTRA IMDxTM solution that allows diagnosing early gastric cancer tissues with a specificity of more than 80 percent compared to the standard white-light endoscopic diagnosis, which yields positive biopsies at a specificity of about 50 percent. This early detection with high specificity will allow the clinicians to treat patients through drugs or minimally invasive therapeutic procedures like Endoscopic Mucosal Resection (EMR) or Endoscopic Submucosal Dissection (ESD). Not to mention, in the current standard of care, after the clinician distinguishes the suspicious lesions through white-light endoscopy, narrow-band imaging is further utilized to study the area for diagnosis. However, this arduous process also demands an experienced and well-trained clinician. "Our IMDx probe is designed to fit into standard endoscope's operational channel of 2.8 mm diameter. This allows the solution to be used with most endoscopes," states Cheng. For the future, Endofotonics is aiming to obtain HSA and CE certification in 2021 and regional certification in SEA in 2022. In order to have a stronger presence in the market, the amalgamated team of scientists, engineers, and clinicians at Endofotonics had spared no effort to deliver a simple and impactful solution. In spite of being a truly groundbreaking solution, the SPECTRA IMDxTM is awaited to be launched commercially. The initial launch of SPECTRA IMDxTM will be SEA with a focus to bring the product into the China market by 2024-25. Also, the additional expansion of indications into the oesophagus and colon area to open the Europe and USA market is planned. Again, Endofotonics is actively looking for more clinical or government collaborations to address the early diagnosis of gastric cancer. HT
< Page 9 | Page 11 >